- Find a Tender
- Contract (Supply)
- not specified
- 20 Jan 2021
- not specified
Nexar platforms and associated consumables to determine the presence or absence of SARS CoV-2 via End Point-PCR from saliva samples. Includes maintenance, support and training associated with the Goods.
| LGC Genomics (Middlesex)
- 38434540 - Biomedical equipment
- 38434500 - Biochemical analysers
- 33696500 - Laboratory reagents
- Award on basis of price.
Following an earlier contract award to LGC on 23 August 2020 for an initial purchase of Nexar platforms, the machines have now successfully passed the required testing and validations.Since the August contract award, there is a requirement for further Nexar platforms (and associated consumables) to be deployed into Mega Labs that are being established to meet national COVID-19 testing targets. DHSC considers that the required deliverables can be supplied only by LGC because the competition is absent for technical reasons, no reasonable alternative or substitute exists and the absence of competition is not the result of an artificial narrowing down of the parameters of the procurement.In particular, DHSC considers that there are no other suppliers in the market who are able to offer equipment (which is only available as part of a package including associated consumables) with the potential to achieve the ultra-high levels of testing offered by LGC's Nexar instruments.DHSC has therefore proceeded with the award of the contract to LGC for the supply further Nexar machines and associated consumables using the negotiated procedure without prior publication, pursuant to Regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015 for the purpose of enabling a step-change in COVID-19 testing capacity at the UK Biocentre in Milton Keynes and the upcoming Mega Labs. Within the contract there is an option for additional Nexar platforms, and optional consumables to be called-off as required by DHSC.
- FTS 001179-2021